Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Minisini, A. M.
Right arrow Articles by Puglisi, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minisini, A. M.
Right arrow Articles by Puglisi, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:333-337, 2003
© 2003 European Society for Medical Oncology

Clinical Investigations

Taxane-induced nail changes: incidence, clinical presentation and outcome

A. M. Minisini1, A. Tosti2, A. F. Sobrero3, M. Mansutti4, B. M. Piraccini2, C. Sacco4 and F. Puglisi1,+

1 Clinical Oncology, University of Udine, Udine; 2 Department of Dermatology, University of Bologna, Bologna; 3 Clinical Oncology, San Martino Hospital, Genoa; 4 Clinical Oncology, General Hospital, Udine, Italy

Received 5 June 2002; accepted 3 July 2002

Abstract

The clinical characteristics of nail changes in seven patients receiving taxane-containing chemotherapy are described. They include nail pigmentation, subungual hematoma, Beau’s lines and onycholysis and subungual suppuration.

The incidence of such changes (ranging from 0% to 44%) is reviewed from a Medline search of the literature.

Key words: chemotherapy, nail changes, side-effects, taxanes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
P. Gilbar, A. Hain, and V.-M. Peereboom
Nail Toxicity Induced by Cancer Chemotherapy
Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 143 - 155.
[Abstract] [PDF]

Home page
 J Hand Surg Eur VolHome page
S. Rall, J. A. Lohmeyer, H.-G. Machens, and P. Mailander
Re: Acute onycholysis during chemotherapy with Doxetacel (Toxotere(R))
J Hand Surg Eur Vol., April 1, 2008; 33(2): 214 - 215.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Hong, S. H. Park, S. J. Choi, S. H. Lee, K. C. Lee, J.-I. Lee, S. Y. Kyung, C. H. An, S. P. Lee, J. W. Park, et al.
Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., June 21, 2007; (2007) hym042v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. R. Bird, T. Elfiki, O. Tucker, and S. O'Reilly
Unilateral nail changes secondary to adriamycin: the protective effect of brachial plexopathy
Ann. Onc., March 1, 2006; 17(3): 527 - 527.
[Full Text] [PDF]

Home page
 JCOHome page
F. Scotte, J.-M. Tourani, E. Banu, M. Peyromaure, E. Levy, S. Marsan, E. Magherini, E. Fabre-Guillevin, J.-M. Andrieu, and S. Oudard
Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand
J. Clin. Oncol., July 1, 2005; 23(19): 4424 - 4429.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
U. De Giorgi, G. Rosti, M. Monti, G. L. Frassineti, and M. Marangolo
Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL)
Ann. Onc., October 1, 2003; 14(10): 1588 - 1589.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Munoz, R. Barcelo, I. Rubio, J. M. Mane, J. Ferreiro, and G. Lopez-Vivanco
Onycholysis Associated With Capecitabine in Combination With Irinotecan in Two Patients With Colorectal Cancer
J Natl Cancer Inst, August 20, 2003; 95(16): 1252 - 1253.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.